摘要
目的 探讨血必净注射液对毛细血管渗漏综合征(CLS)的治疗作用和安全性.方法 选择天津中医药大学第一附属医院综合重症加强治疗病房(ICU)2015年11月至2016年10月收治的临床诊断为CLS患者77例.将患者按随机数字表法分为对照组(35例)和血必净组(42例).对照组行常规治疗的同时积极治疗原发病,血必净组在对照组基础上给予血必净注射液100 mL+0.9%生理盐水100 mL静脉滴注(静滴),每日2次,5 d为1个疗程.比较两组患者治疗前和治疗后5 d白细胞计数(WBC)、中性粒细胞比例(N)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、尿素氮(BUN)、血肌酐(SCr)、降钙素原(PCT)、pH值、动脉血氧分压(PaO2)、乳酸(Lac)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、血小板计数(PLT)的差异,并进行急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分;统计两组患者入住ICU时间、机械通气时间和28 d存活率.结果 血必净组治疗后WBC、N、PCT、ALT、AST、BUN、SCr、Lac、APACHEⅡ评分均较对照组降低〔WBC(×109/L):9.85±0.61比13.87±2.58,N:0.75±0.08比0.90±0.10,PCT(μg/L):1.13±0.71比4.99±1.38,ALT(U/L):79.56±30.85比84.21±27.32,AST(U/L):91.98±38.10比110.28±35.79,BUN(mmol/L):7.35±0.82比8.57±1.43,SCr(μmol/L):111.67±43.96比132.51±55.10,Lac(mmol/L):1.88±1.01比3.31±1.46,APACHEⅡ评分(分):11.34±3.59比17.65±4.77〕;PaO2、PLT、28 d存活率均较对照组明显升高〔PaO2(mmHg,1 mmHg=0.133 kPa):75.47±21.10比54.22±15.23,PLT(×109/L):211.54±58.25比153.27±49.69,28 d存活率:85.71%(36/42)比71.43%(25/35),均P〈0.05〕;PT、APTT、 入住ICU时间和机械通气时间均较对照组缩短〔PT(s):13.62±2.11比18.45±4.26,APTT(s):31.33±4.27比36.85±5.56,入住ICU时间(d):12.4±3.7比20.5±4.1,机械通气时间(d):10.5±4.9比18.7±5.5,均P〈0.05〕.结论 血必净注射液可减轻CLS患者病情,降低炎性指标水平,改善患者凝血功能和低氧血症状况,缩短机械通气时间和入住ICU时间,提高28 d存活率,对肝肾功能无不良影响.
Objective To explore the safety and therapeutic effect of Xuebijing injection for treatment of patients with capillary leak syndrome (CLS).Methods Seventy-seven patients with clinical diagnosis of CLS admitted to Intensive Care Unit (ICU) of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine (TCM) from November 2015 to October 2016 were enrolled, they were divided into a control group (35 cases) and a Xuebijing group (42 cases) according to random number table method. The conventional treatment was given and at the same time the primary disease was actively treated in the control group; while in the Xuebijing group, on the basic treatment of the control group, additionally, Xuebijing injection 100 mL+ 0.9% normal saline (100 mL) was intravenously dripped, twice a day, 5 days constituting one therapeutic course. Before and after treatment for 5 days, the white blood cell count (WBC), neutrophils percentage (N), alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), serum creatinine (SCr), procalcitonin (PCT), pH value, partial pressure of blood oxygen (PaO2), blood lactic acid value (Lac), activated partial thromboplastin time (APTT), prothrombin time (PT), blood platelet count (PLT) in the patients of the two groups were compared; and the acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ) score was recorded; the length of stay in ICU, mechanical ventilation time, and 28-day survival rate were statistically calculated in two groups.Results After treatment, the levels of WBC, N, PCT, ALT, AST, BUN, SCr, Lac, APACHE Ⅱ score in Xuebijing group were lower than those in the control group [WBC(×109/L): 9.85±0.61 vs. 13.87±2.58, N: 0.75±0.08 vs. 0.90±0.10, PCT (μg/L): 1.13±0.71 vs. 4.99±1.38, ALT (U/L): 79.56±30.85 vs. 84.21±27.32, AST (U/L): 91.98±38.10 vs. 110.28±35.79, BUN (mmol/L): 7.35±0.82 vs. 8.57±1.43, SCr (μmol/L): 111.67±43.96 vs. 132.51±55.10, Lac (mmol/L): 1.88±1.01 vs. 3.31±1.46, APACHE Ⅱ score: 11.34±3.59 vs. 17.65±4.77]; the PaO2, PLT, 28-day survival rate in Xuebijing group were higher than those in the control group [PaO2 (mmHg, 1 mmHg = 0.133 kPa): 75.47±21.10 vs. 54.22±15.23, PLT (×109/L): 211.54±58.25 vs. 153.27±49.69, 28-day survival rate: 85.71% (36/42) vs. 71.43% (25/35), allP 〈 0.05]; the PT, APTT, ICU hospitalization time and mechanical ventilation time in Xuebijing group were shorter than those in the control group [PT (s): 13.62±2.11 vs. 18.45±4.26, APTT (s): 31.33±4.27 vs. 36.85±5.56, length of stay in ICU (days): 12.4±3.7 vs. 20.5±4.1, mechanical ventilation time (days): 10.5±4.9 vs. 18.7±5.5, allP 〈 0.05].Conclusion The application of Xuebijing injection for treatment of patients with CLS can relieve their disease situation, reduce inflammatory indicators, improve the blood coagulation function and hypoxemia, shorten the ICU hospitalization time and mechanical ventilation time, elevate the 28-day survival rate, and has no harmful effects on liver and kidney functions.
出处
《中国中西医结合急救杂志》
CAS
CSCD
北大核心
2017年第3期274-277,299,共5页
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care